HIV DART and Emerging Viruses: Frontiers in Drug Development and Antiretroviral Therapies

HIV DART 和新兴病毒：药物开发和抗逆转录病毒疗法的前沿

• 批准号: 10515647
• 负责人: Raymond Felix Schinazi
• 金额: $ 2万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-11-13 至 2023-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10515647
• 关键词: Accreditation; Acquired Immunodeficiency Syndrome; Adherence; Applications Grants; Area; Biology; Chemistry; Chikungunya fever; Childhood; Chronic; Clinical; Clinical Research; Communicable Diseases; Communities; Dengue Fever; Development; Disease; Disease remission; Drug Kinetics; Ebola; Education; Educational workshop; Elderly; Ensure; Face; Formulation; Future; HIV; HIV Infections; HIV/AIDS; Health Personnel; Health Professional; Health Services Accessibility; Hepatitis B; Hepatitis C virus; Individual; Inflammation; International; Knowledge; Learning; Location; Medical; Methods; Nurses; Oral; Pharmaceutical Preparations; Pharmacology; Physicians; Population; Postdoctoral Fellow; Research Personnel; Retroviridae; Role; Scholarship; Scientist; Serology; System; Therapeutic; Therapeutic Agents; Time; Training; Treatment Protocols; United States; United States National Institutes of Health; Viral; Viral reservoir; Virus; Yellow Fever; antiretroviral therapy; antiviral drug development; co-infection; continuing medical education; design; drug development; drug metabolism; frontier; graduate student; improved; lectures; microbicide; neuroAIDS; novel; novel therapeutics; posters; programs; side effect; symposium; treatment as prevention; vaccine development; zika fever

Abstract/Project Summary Thanks to advances in antiretroviral therapy, the face of HIV and AIDS has been gradually and meaningfully transformed from a deadly disease, into a chronic condition that is managed with careful adherence to life-long treatment regimens. The need for improved drugs, with fewer side-effects, improved adherence and more favorable pharmacokinetics increases as the number of infected individuals on long-term therapy continues to rise. Importantly, the quest for an HIV cure continues to gain momentum as we learn more about viral reservoirs and mechanisms of viral persistence. HIV DART and Emerging Viruses is a biennial conference for physicians, clinicians, nurses, scientists and clinical researchers that will focus on the latest discoveries in these areas. Specific Aims: 1. Gather cross-disciplinary professionals such as clinicians, health care workers, researchers and basic scientists together in an interactive workshop setting to share and discuss the latest developments in the field of HIV and emerging viruses; 2. Facilitate the neutral and balanced exchange of scientific knowledge with regard to antiviral drug development, vaccine development, and recent progress in curative strategies; 3. Enhance the training of young scientists such as graduate students and post-doctoral fellows and provide increased opportunities for underrepresented scientists and health care workers through attendee scholarships. Educational Objectives: 1. Identify novel therapeutic agents and viral targets for HIV, retroviruses and other emerging viruses; 2. Understand HIV reservoirs and viral persistence; 3. Discuss novel remission, cure, and eradication strategies for HIV; 4. Discuss inflammation in the context of HIV infection, neuroAIDS and AIDS in geriatric and pediatric populations; 5. Understand drug metabolism and pharmacology and discuss improved formulations; 6. Discuss treatment access, treatment as prevention and the role of microbicides; 7. Discuss HIV treatment in the context of co-infection with Hepatitis B or hepatitis C virus; 8. Discuss recent advances in vaccine development and systems serology; 9. Discuss recent scientific discoveries with regard to emerging viral threats such as Ebola, Zika, chikungunya, dengue and yellow fever. Design & Methods: HIV DART and Emerging Viruses will take place in the United States of America over a 2.5 days period, at a location that is easily accessed by both national and international delegates. The program will include plenary lectures, oral abstract presentations, discussion panels and a debate. This ACCME-accredited program will provide ample time for formal and informal networking and discussion amongst the delegates during the poster session and meal breaks.

摘要/项目摘要 由于抗逆转录病毒治疗的进步，艾滋病毒和艾滋病的面貌逐渐 并有意义地从一种致命的疾病转变为一种慢性疾病 小心翼翼地坚持终身治疗方案。需要改进的药物，更少的药物 副作用、更好的依从性和更有利的药代动力学随着 接受长期治疗的感染者的比例继续上升。重要的是，对艾滋病毒的追求 随着我们对病毒库和病毒机制的更多了解，CURE继续获得动力 病毒持久力。HIV DART和新兴病毒是两年一度的内科医生会议， 临床医生、护士、科学家和临床研究人员将重点介绍 这些区域。 具体目标：1.聚集临床医生、医疗保健等跨学科专业人员 工作人员、研究人员和基础科学家一起在互动研讨会上分享 并讨论艾滋病毒和新出现病毒领域的最新发展；2.促进 中立和平衡地交流有关抗病毒药物的科学知识 发展、疫苗开发和治疗策略的最新进展；3.加强 培训青年科学家，如研究生和博士后研究员，并提供 通过以下方式增加代表不足的科学家和卫生保健工作者的机会 出席者奖学金。教育目标：1.发现新的治疗药物和病毒 针对艾滋病毒、逆转录病毒和其他新出现的病毒；2.了解艾滋病毒宿主和病毒 坚持不懈；3.讨论新的艾滋病毒缓解、治愈和根除策略；4.讨论 老年和儿童中艾滋病毒感染、神经艾滋病和艾滋病背景下的炎症 了解药物代谢和药理学，并讨论改进 配方；6.讨论治疗途径、作为预防的治疗和杀菌剂的作用； 7.在与乙肝或丙型肝炎病毒混合感染的情况下讨论艾滋病毒的治疗； 讨论疫苗开发和系统血清学方面的最新进展；9.讨论最新进展 关于埃博拉、寨卡、基孔肯雅热等新出现病毒威胁的科学发现， 登革热和黄热病。设计与方法：HIV DART和新兴病毒将在 美利坚合众国在2.5天的时间内，在一个双方都可以轻松进入的地点 国家和国际代表。该计划将包括全体讲座、口头摘要 演讲、讨论小组和一场辩论。这一经ACCME认证的计划将提供 在会议期间，代表们有充足的时间进行正式和非正式的联系和讨论 海报会议和用餐时间。